{"id":"terizidone","rwe":[],"tags":[{"label":"terizidone","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"J04AK03","category":"atc"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{"safetySignals":[{"llr":130.088,"date":"","count":40,"signal":"Myelosuppression","source":"DrugCentral FAERS","actionTaken":"Reported 40 times (LLR=130)"},{"llr":121.197,"date":"","count":40,"signal":"Drug resistance","source":"DrugCentral FAERS","actionTaken":"Reported 40 times (LLR=121)"},{"llr":104.85,"date":"","count":31,"signal":"Polyneuropathy","source":"DrugCentral FAERS","actionTaken":"Reported 31 times (LLR=105)"},{"llr":94.297,"date":"","count":39,"signal":"Electrocardiogram QT prolonged","source":"DrugCentral FAERS","actionTaken":"Reported 39 times (LLR=94)"},{"llr":68.627,"date":"","count":56,"signal":"Anaemia","source":"DrugCentral FAERS","actionTaken":"Reported 56 times (LLR=69)"},{"llr":61.29,"date":"","count":36,"signal":"Neuropathy peripheral","source":"DrugCentral FAERS","actionTaken":"Reported 36 times (LLR=61)"},{"llr":60.862,"date":"","count":14,"signal":"Bicytopenia","source":"DrugCentral FAERS","actionTaken":"Reported 14 times (LLR=61)"},{"llr":56.387,"date":"","count":38,"signal":"Treatment failure","source":"DrugCentral FAERS","actionTaken":"Reported 38 times (LLR=56)"},{"llr":56.083,"date":"","count":22,"signal":"Psychotic disorder","source":"DrugCentral FAERS","actionTaken":"Reported 22 times (LLR=56)"}],"commonSideEffects":[{"effect":"Myelosuppression","drugRate":"LLR 130","severity":"common"},{"effect":"Drug resistance","drugRate":"LLR 121","severity":"common"},{"effect":"Polyneuropathy","drugRate":"LLR 105","severity":"common"},{"effect":"Electrocardiogram QT prolonged","drugRate":"LLR 94","severity":"common"},{"effect":"Anaemia","drugRate":"LLR 69","severity":"common"},{"effect":"Neuropathy peripheral","drugRate":"LLR 61","severity":"common"},{"effect":"Bicytopenia","drugRate":"LLR 61","severity":"common"},{"effect":"Treatment failure","drugRate":"LLR 56","severity":"common"},{"effect":"Psychotic disorder","drugRate":"LLR 56","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"terizidon","offLabel":[],"synonyms":["terizidone","terivalidin","terizidon"],"timeline":[],"approvals":[],"brandName":"Terizidon","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"terizidone","explanation":"Think of it like a key that unlocks a door. In this case, the key is terizidone, and the door is the brain's ability to make certain chemicals that can cause problems. By blocking these chemicals, terizidone can help reduce symptoms of certain conditions.","oneSentence":"Terizidone works by inhibiting the activity of certain enzymes in the brain.","technicalDetail":"Terizidone is a non-selective inhibitor of monoamine oxidase (MAO) enzymes, specifically MAO-A and MAO-B, which play a crucial role in the breakdown of monoamine neurotransmitters such as serotonin, dopamine, and norepinephrine."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2602","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=TERIZIDONE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TERIZIDONE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:51:02.739163","biosimilars":[],"competitors":[{"drugName":"pyrazinamide","drugSlug":"pyrazinamide","fdaApproval":"1971-06-03","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ethambutol","drugSlug":"ethambutol","fdaApproval":"1967-11-06","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"bedaquiline","drugSlug":"bedaquiline","fdaApproval":"2012-12-28","patentExpiry":"Mar 19, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"pretomanid","drugSlug":"pretomanid","fdaApproval":"2019-08-14","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"terizidone","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"pyrazinamide","brandName":"pyrazinamide","genericName":"pyrazinamide","approvalYear":"1971","relationship":"same-class"},{"drugId":"ethambutol","brandName":"ethambutol","genericName":"ethambutol","approvalYear":"1967","relationship":"same-class"},{"drugId":"bedaquiline","brandName":"bedaquiline","genericName":"bedaquiline","approvalYear":"2012","relationship":"same-class"},{"drugId":"pretomanid","brandName":"pretomanid","genericName":"pretomanid","approvalYear":"2019","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":["HIV Infections"],"enrollment":1578,"completionDate":"2020-09-30"},{"nctId":"NCT03237182","phase":"PHASE4","title":"The Individualized M(X) Drug-resistant TB Treatment Strategy Study","status":"TERMINATED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2017-06-14","conditions":["Tuberculosis, Multidrug-Resistant"],"enrollment":205,"completionDate":"2022-12-19"},{"nctId":"NCT02454205","phase":"PHASE2,PHASE3","title":"An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2015-11-12","conditions":["Tuberculosis","Multidrug Resistant Tuberculosis","Extensively-drug Resistant Tuberculosis"],"enrollment":154,"completionDate":"2021-08-30"},{"nctId":"NCT03625739","phase":"","title":"Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis","status":"RECRUITING","sponsor":"Beijing Children's Hospital","startDate":"2018-07-01","conditions":["Tuberculosis"],"enrollment":800,"completionDate":"2026-12-31"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"005992","UNII":"1199LEX5N8","CHEBI":"CHEBI:135278","INN_ID":"1707","RXNORM":"57047","UMLSCUI":"C0145184","ChEMBL_ID":"CHEMBL2107553","KEGG_DRUG":"D07247","DRUGBANK_ID":"DB12954","PUBCHEM_CID":"65720","MESH_SUPPLEMENTAL_RECORD_UI":"C100142"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":70,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"J04AK03","allCodes":["J04AK03"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Terizidon is a small molecule used in the treatment of tuberculosis, including multidrug-resistant and extensively-drug resistant forms, as well as HIV infections. It is administered as part of individualized or standardized treatment regimens, often in combination with other drugs.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}